Mechanisms of fluoroquinolone resistance in Pseudomonas aeruginosa isolates from canine infections

Veterinary Microbiology

Volumn 94, Issue 4, 2003, Pages 295-301

  Tejedor, María Teresa ^a   Martín, Jose Luis ^a   Navia, Margarita ^b   Freixes, Joan ^c   Vila, Jordi ^b  

^a UNIVERSITY OF LAS PALMAS DE GRAN CANARIA   (Spain)

^b HOSPITAL CLÍNIC   (Spain)

^c Cenavisa SA   (Spain)

Author keywords

Dog; Fluoroquinolones; Mechanisms of resistance; Otitis externa; Pseudomonas aeruginosa

Indexed keywords

CIPROFLOXACIN; DANOFLOXACIN; DIFLOXACIN; ENROFLOXACIN; MARBOFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL GENE; BACTERIAL STRAIN; BACTERIUM ISOLATE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE ASSOCIATION; DOG; DRUG EFFECT; DRUG MECHANISM; DRUG SCREENING; EXTERNAL OTITIS; GENE MUTATION; GENE OVEREXPRESSION; GRAM NEGATIVE INFECTION; LIPOPHILICITY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PSEUDOMONAS AERUGINOSA;

CANIS FAMILIARIS; PSEUDOMONAS; PSEUDOMONAS AERUGINOSA;

EID: 0038460959     PISSN: 03781135     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0378-1135(03)00129-9     Document Type: Article

References (25)

1. Everett M.J., Fang Jin Y., Ricci V., Piddock L.J.V. Contribution of individual mechanisms to fluoroquinolone resistance in 36 Escherichia coli strains isolated from humans and animals. Antimicrob. Agents Chemother. 40:1996;2380-2386.
2. Foster A.P., De Boer D.J. The role of Pseudomonas in canine ear disease. Comp. Cont. Educ. Pract. Vet. 20:1998;909-919.
3. Gilbert D.N., Kohlhepp S.J., Slama A., Grunkemeier G., Lewis G., Dworkin R.J., Slaughter S.E., Leggett J.E. Phenotypic resistance of Staphylococcus aureus, selected Enterobacteriaceae and Pseudomonas aeruginosa after single and multiple in vitro exposures to ciprofloxacin, levofloxacin and trovafloxacin. Antimicrob. Agents Chemother. 45:2001;883-892.
4. Giraud E., Leroy-Sétrin S., Flaujac G., Cloeckaert A., Dho-Moulin M., Chaslus-Dancla E. Characterization of high-level fluoroquinolone resistance in Escherichia coli O78:K80 isolated from turkeys. J. Antimicrob. Chemother. 47:2001;341-343.
5. Ihrke P.J., Papich M.G., Demanuelle T.C. The use of fluoroquinolones in veterinary dermatology. Vet. Dermatol. 10:1999;193-204.
6. Li X.Z., Nikaido H., Poole K. Role of mexA-mexB-oprM in antibiotic efflux in Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 39:1995;1948-1953.
7. Lomovskaya O., Warren M.S., Lee A., Galazzo J., Fronko R., Lee M., Blais J., Cho D., Chamberland S., Renau T., Leger R., Hecker S., Watkins W., Hoshino K., Ishida H., Lee V.J. Identification and characterization of inhibitors of multidrug resistance efflux pumps in Pseudomonas aeruginosa: novel agents for combination therapy. Antimicrob. Agents Chemother. 45:2001;105-116.
8. Meylan W.M., Howard P.H. Atom/fragment contribution method for estimating octanol-water partition coefficients. J. Pharm. Sci. 84:1995;83-92.
9. Nakano M., Deguchi T., Kawamura T., Yasuda M., Kimura M., Okano Y., Kawada Y. Mutations in the gyrA and parC genes in fluoroquinolone-resistant clinical isolates of Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 41:1997;2289-2291.
10. National Committee for Clinical Laboratory Standards, 1997. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically. 4th ed. Approved standard. NCCLS document M7-A4. National Committee for Clinical Laboratory Standards, Wayne, PA.
11. National Committee for Clinical Laboratory Standards, 1999. Performance Standards for Antimicrobial Disk and Dilution Susceptibility Tests for Bacteria Isolated from Animals. Approved standard. NCCLS document M31-A. National Committee for Clinical Laboratory Standards, Wayne, PA.
12. Nikaido H. Multidrug efflux pumps of Gram-negative bacteria. J. Bacteriol. 178:1996;5853-5859.
13. Okuzu H., Ma D., Nikaido H. AcrAB efflux pump plays a major role in the antibiotic resistance phenotype of Escherichia coli multiple antibiotic resistance (Mar) mutants. J. Bacteriol. 178:1996;306-308.
14. Peña C., Albareda J.M., Pallares R., Pujol M., Tubau F., Ariza J. Relationship between quinolone use and emergence of ciprofloxacin resistant Escherichia coli in bloodstream infections. Antimicrob. Agents Chemother. 39:1995;520-524.
15. Piddock L.J. Mechanisms of fluoroquinolone resistance: an update 1994-1998. Drugs. 58(Suppl. 2):1999;11-18.
16. Riddle C., Lemons C.L., Papich M.G., Altier C. Evaluation of ciprofloxacin as a representative of veterinary fluoroquinolones in susceptibility testing. J. Clin. Microbiol. 38:2000;1636-1637.
17. Takenouchi T., Sakagawa E., Sugawara M. Detection of gyrA mutations among 335 Pseudomonas aeruginosa strains isolated in Japan and their susceptibilities to fluoroquinolones. Antimicrob. Agents Chemother. 43:1999;406-409.
18. Vila J., Ruiz J., Marco F., Barceló A., Goñi P., Giralt E., Jiménez de Anta T. Association between double mutation in gyrA gene of ciprofloxacin resistant clinical isolates of Escherichia coli and MICs. Antimicrob. Agents Chemother. 38:1994;2477-2479.
19. Vila J., Ruiz J., Goñi P., Jiménez de Anta M.T. Detection of mutations in parC in quinolone-resistant clinical isolates of Escherichia coli. Antimicrob. Agents Chemother. 40:1996;491-493.
20. Vila J., Ruiz J., Navia M.M. Molecular bases of quinolone resistance acquisition in Gram-negative bacteria. Recent Res. Dev. Antimicrob. Agents Chemother. 3:1999;323-344.
21. Webber M.A., Piddock L.J.V. Absence of mutation in marRAB or soxRS in acrB-overexpressing fluoroquinolone-resistant clinical veterinary isolates of Escherichia coli. Antimicrob. Agents Chemother. 45:2001;1550-1552.
22. White P.D. Medical management of chronic otitis in dogs. Comp. Cont. Educ. Pract. Vet. 21:1999;716-728.
23. White D.G., Piddock L.J.V., Maurer J.J., Zhao S., Ricci V., Thayer S.G. Characterization of fluoroquinolone resistance among veterinary isolates of avian Escherichia coli. Antimicrob. Agents Chemother. 44:2000;2897-2899.
24. Wolfson J.S., Hooper D.S. The fluoroquinolones: structures, mechanisms of action and resistance, and spectra of activity in vitro. Antimicrob. Agents Chemother. 28:1985;581-586.
25. Yonezawa M., Takahata N., Matsubara M., Watanabe Y., Narita H. DNA gyrase gyrA mutations in quinolone-resistant clinical isolates of Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 39:1995;1970-1972.